Biochemical Engineering Special Interest Group
biological engineering professionals
28 October 2016

Adaptimmune signs Keytruda/T-cell therapy myeloma tie-up with Merck

Small cap British biotech Adaptimmune will combine its experimental NY-ESO SPEAR T-cell therapy with Merck’s ($MRK) blockbuster checkpoint inhibitor Keytruda (pembrolizumab) for tests in myeloma. The hope is that a combination deal, which is all the rage with PD-1 and PD-L1 meds right now, will boost efficacy in fighting off cancer, and also help the body’s immune system attack the disease. Source: Fierce Biotech 28/10/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).